Novo's semaglu­tide hand­i­ly whips Eli Lil­ly's Trulic­i­ty in a PhI­II di­a­betes show­down

No­vo Nordisk had some more up­beat pipeline news to re­port Wednes­day af­ter­noon, as re­searchers rolled out new Phase III da­ta show­ing their GLP-1 drug semaglu­tide — a would-be block­buster — beat out Eli Lil­ly’s Trulic­i­ty (du­laglu­tide) in a head-to-head show­down.

Of par­tic­u­lar note: No­vo’s drug sailed through SUS­TAIN 7 with com­pa­ra­ble in­stances of di­a­bet­ic retinopa­thy with the com­para­tor drug from Lil­ly. That may help qualm fears raised by ear­li­er study re­sults.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.